ketorolac has been researched along with Anoxemia in 4 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seeger, DR | 1 |
| Golovko, SA | 1 |
| Grove, BD | 1 |
| Golovko, MY | 1 |
| Markwald, RR | 1 |
| Kirby, BS | 1 |
| Crecelius, AR | 1 |
| Carlson, RE | 1 |
| Voyles, WF | 1 |
| Dinenno, FA | 1 |
| Palayoor, ST | 1 |
| Tofilon, PJ | 1 |
| Coleman, CN | 1 |
| Blackburn, A | 1 |
| Stevens, JD | 1 |
| Wheatley, RG | 1 |
| Madej, TH | 1 |
| Hunter, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery[NCT03805607] | Phase 4 | 40 participants (Actual) | Interventional | 2021-01-18 | Active, not recruiting | ||
| A Prospective, Randomized, Control Trial of Ketorolac Versus Placebo on Opioid Analgesic Use, Estimated Blood Loss and Complications Following Cesarean Delivery With Epidural Morphine[NCT02509312] | Phase 4 | 70 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total doses of medications to treat pruritus (opioid side-effect) including ondansetron and promethazine. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | doses (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Corrected change in Hct on POD1. Performed by subtracting POD1 Hct from POD0 Hct. Correction for transfusion by further subtracting 3 per unit of pRBC transfused to account for the typical change seen per unit transfused. (NCT02509312)
Timeframe: POD1
| Intervention | mg/dl (Mean) |
|---|---|
| Ketorolac | -5.1 |
| Placebo | -3.5 |
Estimation of blood loss during surgery (NCT02509312)
Timeframe: Immediately post-op
| Intervention | ml (Median) |
|---|---|
| Ketorolac | 900 |
| Placebo | 800 |
Rate of Post-Partum Hemorrhage between groups during the first 24 hours pst-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac | 7 |
| Placebo | 4 |
Total doses of medications to treat pruritus (opioid side-effect) including diphenhydramine, nalbuphine and naloxone. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | doses (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Total hydromorphone doses in mg in the first 24 hours post-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum.
| Intervention | mg (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0.2 |
Total number of Units of Packed Reb Blood Cell Transfused in intra-op until 24 hours post-partum. (NCT02509312)
Timeframe: Intra-op until 24 hours post-partum.
| Intervention | units of pRBCs (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Total number of uterotonic doses including methylergonovine, carboprost and misoprostol. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | doses (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Pain score post-Cesarean Delivery using 11-point numerical rating scale (NRS): 0-10 where 0 is no pain and 10 is the worst pain imaginable (NCT02509312)
Timeframe: Up to 24 hours post-cesarean delivery
| Intervention | units on NRS (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | 15 mins | 1 hour | 6 hours | 12 hours | 24 hours | |
| Ketorolac | 0 | 0 | 0 | 1 | 2 | 4.5 |
| Placebo | 0 | 0 | 0 | 3 | 3.5 | 5.5 |
Percentile change in diastolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | Percent change (Mean) | ||
|---|---|---|---|
| 6 hours | 12 hours | 24 hours | |
| Ketorolac | 12.30 | 8.8 | 12.0 |
| Placebo | 7.6 | 8.8 | 11.1 |
Percentile change in Systolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | Percent change (Mean) | ||
|---|---|---|---|
| 6 hours | 12 hours | 24 hours | |
| Ketorolac | -2.0 | -9.10 | -5.9 |
| Placebo | -0.6 | -2.85 | -3.5 |
2 trials available for ketorolac and Anoxemia
| Article | Year |
|---|---|
Combined inhibition of nitric oxide and vasodilating prostaglandins abolishes forearm vasodilatation to systemic hypoxia in healthy humans.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Blood Flow Velocity; Blood Gas Analysis; Blood Pr | 2011 |
Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Anesthesia; Double | 1995 |
Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Anesthesia; Double | 1995 |
Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Anesthesia; Double | 1995 |
Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Anesthesia; Double | 1995 |
2 other studies available for ketorolac and Anoxemia
| Article | Year |
|---|---|
Cyclooxygenase inhibition attenuates brain angiogenesis and independently decreases mouse survival under hypoxia.
Topics: Angiogenesis Inhibitors; Animals; Chronic Disease; Cyclooxygenase Inhibitors; Dose-Response Relation | 2021 |
Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tu | 2003 |